What’s Happening? → A Pivotal Q2 IR on July 25 to Decide Hanmi’s Fate

Hanmi Pharmaceutical has announced it will hold its Q2 2025 earnings call at 4:30 PM on July 25, 2025. This event will feature a detailed explanation of the Q2 performance and a Q&A session on future business strategies. It is a crucial event for forecasting the short and medium-term trends of Hanmi’s volatile stock.

Why Is It Important? → A Crossroads of Hope and Concern from Q1 Results

In the first quarter, Hanmi achieved positive results with increased operating and net profits, thanks to cost efficiency and growth in the Chinese market. However, significant concerns also emerged, including declining revenue, uncertainty in key pipeline development, and intensifying market competition. Therefore, this Q2 IR is a vital test to see if the company can resolve these concerns and demonstrate sustainable growth.

So What’s the Play? → 5 Key Watch-Points for Investors in the Q2 IR

During this IR, Hanmi’s present and future should be evaluated based on the following five points:

  • 1. Earnings Turnaround: Will It Beat Market Expectations?

    The most crucial factor is the bottom line itself. Whether revenue and operating profit have improved from Q1 and whether the company can deliver an ‘earnings surprise’ that exceeds market expectations will have an immediate impact on the stock price. A continued downward trend in revenue will inevitably dampen investor sentiment.

  • 2. Future Growth Engine: Progress on Key Pipelines

    The core of any pharma/biotech company is its pipeline. Specific updates on the results of ongoing Phase 1, 2, and 3 clinical trials and the status of major licensing-out deals are needed. Positive clinical data or hints at potential milestone payments could act as powerful catalysts for the stock price.

  • 3. Profitability Defense: Cost Management and Overseas Strategy

    The company will likely disclose its cost management know-how, which contributed to Q1 profit improvement, and its specific growth strategies for overseas markets, especially China. Investors should pay close attention to the credibility of its risk management plans for challenges like a slowdown in the Chinese economy or fluctuations in logistics costs.

  • 4. Macroeconomic Risks: FX Rates, Interest Rates, and Commodity Prices

    Given its high dependency on imported raw materials, it’s essential to check the impact of foreign exchange rate fluctuations (KRW/USD, KRW/EUR) on profitability and the company’s response strategy. Also, the company’s analysis and plans regarding the impact of rising interest rates on investment costs and oil price volatility on raw material profitability are key evaluation factors.

  • 5. Restoring Trust: Competition and Governance

    From a long-term perspective, it is also crucial to see how the company addresses intensifying market competition, the regulatory environment, and its efforts to enhance transparency and trust, including preventive measures against past disclosure violations.

Investor Action Plan → What to Verify During the IR Call

If you are considering an investment in Hanmi Pharmaceutical, you must verify the following points during the IR presentation to build your investment strategy:

  • ✔️ Quantitative Metrics: Do the Q2 revenue and operating profit exceed the market consensus?
  • ✔️ Pipeline Updates: Is there positive progress in clinical data? Is a new licensing-out (L/O) deal on the horizon?
  • ✔️ Risk Management: Does the company present a concrete hedging strategy for external risks like currency and commodity price fluctuations?
  • ✔️ Management’s Confidence: Does the Q&A session reveal the management’s conviction and a clear plan for the company’s future vision?

This analysis is based on limited information and is not an investment recommendation. The final investment decision rests with the investor’s own judgment and responsibility.